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Alopecia areata (AA) is thought to be an autoimmune process. In other autoimmune diseases, the 
innate immune system and Toll-like receptors (TLRs) can play a significant role. Expression of 
TLR7, TLR9, and associated inducible genes were evaluated by quantitative PCR in peripheral 
blood mononuclear cells (PBMCs) from 10 healthy individuals and 19 AA patients, categorized 
according to disease duration, activity, and hair loss extent. Microdissected scalp biopsies from 5 
patients and 4 controls were also assessed by quantitative PCR and immunohistology. TLR9 was 
significantly upregulated 2.37 fold in AA PBMCs. Notably, TLR9 was most significantly up 
regulated in patients with active AA, as shown by a positive hair pull test, compared to stable AA 
patients. In hair follicle bulbs from AA patients, IFNG and TLR7 exhibited statistically significant 
3.85 and 2.70 fold increases in mRNA respectively. Immunohistology revealed TLR7 present in 
lesional follicles, while TLR9 positive cells were primarily observed peri-bulbar to AA affected 
hair follicles. The increased expression of TLR7 and TLR9 suggest components of the innate 




The pathogenesis of alopecia areata (AA) involves an autoimmune, lymphocyte-mediated attack 
on hair follicles.[1-6] Peri-bulbar inflammation and hair follicle infiltration by CD4+ and CD8+ 
lymphocytes is a hallmark feature of AA.[4] However, studies on other autoimmune diseases 
suggest the innate immune system can also play a significant role in promoting autoimmunity.[7,8] 
Notably, AA affected skin can also be infiltrated by macrophages, Langerhans cells, dendritic cells, 
natural killer (NK) cells, mast cells, and eosinophils,[9-13] circumstantially suggesting innate 
immune system constituents may also be active in AA.  
 
Analysis of AA patient peripheral blood mononuclear cells (PBMCs) has revealed increased 
expression of mRNA for intracellular toll-like receptors (TLRs).[14] Activation of TLR7 (which 
senses single stranded RNA) and TLR9 (which senses unmethylated CpG dinucleotides in DNA) 
is significantly implicated in systemic lupus erythematosus (SLE).[15] Uptake of DNA/RNA-
immunocomplexes by plasmacytoid dendritic cells (pDCs) activates intracellular TLRs.[16] TLR 
signaling initiates the MyD88 signaling pathway.[17,18] Consequently, type I interferons (eg. IFN, 




Here, we explored the hypothesis that TLR7 and TLR9 and associated inducible genes are 






Written informed consent was obtained from all patients recruited at the Department of 
Dermatology and Skin Science, University of British Columbia, with University Clinical Research 
Ethics Board approval. The following exclusion criteria were applied: patients under the age of 
nineteen and over age 65; a SALT (Severity of Alopecia Tool) score [22] between 30% and 70%; 
co-existing scalp dermatoses or other hair loss conditions; patients with other autoimmune 
disorders, viral or bacterial infections; and patients with any treatment history within the three 
months prior to consultation. Clinical parameters were recorded including age, sex, extent of hair 
loss, and disease duration. Patients were also evaluated by hair pull test for active or stable AA.[23]  
 
Blood sampling and RNA isolation 
Nineteen patients (11 females, 8 males; age range 24–61 years) with AA and 10 healthy controls 
(4 females, 6 males; age range 28–53 years) provided blood samples. Total RNA was extracted 
using the QIAamp RNA blood kit (Qiagen, Mississauga, ON, Canada) according to 
manufacturer’s protocols. RNA was eluted with RNase-free water and samples were stored at -
80°C before quantitative reverse transcriptase-PCR (qPCR) analysis. 
 
Tissue collection and RNA isolation 
For mRNA analysis, AA scalp punch biopsies were obtained from 5 patients (all female; age range 
43-57 years). All patients had active, patchy AA (30–50% lesional area) and were not receiving 
treatment. Specimens were obtained under local anesthesia from the lesional margin (M) of AA 
patches and externally normal looking perilesional (P) scalp skin at least 2cm from the lesional 
margin and negative for a hair pull test. Four scalp skin specimens were obtained from normal 
haired subjects during cosmetic surgery (3 females, 1 male; age range 34-59 years) as controls. All 
tissue samples were placed in RNA stabilizing reagent (RNAlater; Qiagen). Hair follicles were 
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isolated from the skin biopsies by microdissection under a stereo microscope as previously 
described.[24] Telogen stage hair follicles were discarded based on length and absence of a 
recognizable hair bulb. The hair bulbs of anagen and dystrophic anagen hair follicles were 
amputated (n>20 per biopsy). Total RNA was extracted using the RNeasy fibrous tissue kit 
(Qiagen) according to manufacturer’s protocols. 
 
Real-time reverse transcription-PCR analysis for gene expression  
TLR7, TLR9 and select interferon inducible genes were chosen for qPCR analysis (Supplemental 
Table 1) and primers designed as described elsewhere.[25] RNA was reverse transcribed into cDNA 
with the SuperScript™ II Reverse Transcriptase kit (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA). Real-time qPCR was performed with a SYBR Green Master mix system 
(Finnzymes, Espoo, Finland) according to the manufacturer's protocols. Universal 18S primers 
(Ambion, Austin, TX) were used for all analyses described and qPCR data was normalized against 
18S expression.  
 
Immunohistology 
For immunohistology, AA scalp skin tissue samples were taken from the margin of active lesions 
of 6 patients (all female; age range 33-52 years). All patients had active, patchy AA (30–50% 
lesional area) and were not receiving treatment. Scalp tissue derived from 3 normal subjects during 
cosmetic surgery was utilized as comparative controls (2 females, 1 male; age range 35-59 years). 
All tissue samples were fixed in 10% formalin and processed routinely to glass slides. Paraffin 
embedded tissue sections were rehydrated, antigen unmasked with sodium citrate buffer, and 
hydrogen peroxide was used to block endogenous peroxidase as described elsewhere.[26] Sections 
were incubated with goat anti-human TLR7 and 9 polyclonal antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA), and biotinylated secondary antibodies (Jackson ImmunoResearch, 
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West Grove, PA) Isotype-matched antibodies were utilized as negative controls. The color reaction 
was produced using the 3,3'-diaminobenzidine substrate (Vector Laboratories, Burlingame, CA). 
 
Statistical analysis 
Patients were categorized based on their extent of scalp hair loss (less than 30% versus more than 
70% by SALT score calculation), hair loss duration (acute, less than 6 months versus chronic, 
more than 6 months), and disease progression or stability (positive hair pull test versus a negative 
result). The qPCR data were analyzed using the comparative cycle threshold method (Ct) (Δ Δ Ct) 
representing the change in mRNA expression relative to control.[27] Results are expressed as the 
fold change in transcript levels for AA patients compared to controls. The difference in gene 





Differential gene expression in AA PBMCs  
PBMCs from AA patients had significantly higher TLR9 mRNA levels compared to controls 
(Supplemental table 2). The mean fold change in mRNA levels for GBP, MDA5, IFNA2, MX1, 
IFIT, TLR7, and DDX were higher in AA patients compared to controls (Figure 1). However the 
difference did not reach statistical significance, reflecting significant variability in expression 
between individual samples. Mean mRNA levels for IFNG, IFNGR1, IFNGR2, IFNA1, IFNB1, 
IFI44, and IRF1 were lower than controls, but also did not reach statistical significance.  
 
In patients with a SALT score less than 30%, TLR9 mRNA levels in PBMCs were significantly up 
regulated compared to controls (Supplemental Figure 1). Though statistical significance was not 
 8 
achieved, there was a trend for increased TLR9 in patients presenting with AA of duration greater 
than 6 months (supplemental Figure 2). In active AA patients, IFNG mRNA was significantly 
down regulated. Notably, TLR9 was significantly up regulated in active AA compared to stable 
AA patients (Supplemental Figure 3). 
 
Differential gene expression in follicular bulbs of the lesional AA margin and perilesion  
Among genes evaluated in hair follicle bulbs (both lesional margin and perilesion combined), 
IFNG and TLR7 exhibited statistically significant fold increases. In contrast, IFNGR2, IFNA1, 
IFIT1, and GBP exhibited significant fold decreases in expression (Figure 1, supplemental table 2). 
When the mRNA expression of the perilesional hair follicles were evaluated against controls, 
IFNG mRNA was significantly upregulated. TLR7 mRNA showed modest upregulation, but 
without statistical significance. In contrast, several genes in perilesional hair follicles showed a 
trend for down regulation in mRNA achieving statistical significance for IFNGR2, IFNA1, IFNA2, 
IFIT1, IFI44, and GBP (Supplemental Figure 4). Hair follicle bulbs from AA lesional margins 
showed greater than 2 fold increases in IFNG, IFNB1, IFI44, IRF1, TLR7 and TLR9, but none 
achieved statistical significance. 
 
Toll like receptor expression and immunolocalization in alopecic lesions 
TLR7 and TLR9 were evaluated by immunohistochemistry in 6 patients with AA and 3 control 
scalp biopsies. TLR7 expression was consistently expressed in the outer root sheath and bulb 
region in AA lesion specimens while no positive cells were seen in control tissues. TLR9 positive 
cells were variably observed exterior to AA affected hair follicles possibly consistent with 






TLR7 and TLR9 are located on cell endosomal membranes where they detect virus-derived RNA 
and DNA, inducing expression of antiviral genes including IFNs.[28] Deregulated production of 
IFNs is associated with several autoimmune diseases.[29-31] In our analysis, TLR9 mRNA 
expression was significantly upregulated in AA patient PBMCs and there was a trend for increased 
TLR9 mRNA expression in follicle bulbs of AA patients. TLR7 expression was significantly 
increased in preilesional and lesional margin follicular bulbs. We did not conduct any functional 
studies and as such, it is possible that the expression of TLR7 and TLR9 in AA are secondary and 
not significant to disease pathogenesis. However, systemic lupus erythematosus and multiple 
sclerosis studies suggest TLRs are important mediators of the inflammatory response.[32,33] While 
the functional significance of TLRs in AA remains to be explored, their increased expression may 
indicate a role in AA. Of note, TLR1 polymorphisms may be related to AA susceptibility.[34] 
 
Type II interferon IFNγ plays an important role in AA;[35-37] IFNγ deficient mice are resistant to 
AA development.[38,39] Here, IFNG mRNA expression was reduced in AA patient PBMCs, 
perhaps consistent with limited expression during cell transit.[40,41] Other studies have suggested 
both increases [35] and decreases [42] in IFNγ in AA PBMCs. We observed a significant increase in 
IFNG mRNA expression in AA affected hair follicles consistent with prior observations.[43-45] 
Previous publications suggest type I IFNs may also be active in AA,[46,47] and AA can develop in 
subjects receiving IFNα/β treatment.[48-50] However, inconsistent with activation of antiviral 
pathways, we observed reduced expression of several IFN inducible genes in AA PBMCs and 
follicle bulbs. Alternatively, TLR expression can promote, and be promoted by, proinflammatory 
cytokines, including IFN,[51-53] which may be the case here.  
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Our data suggest upregulated TLR7 and TLR9 expression is associated with AA development 
while multiple associated inducible genes are downregulated. Although our study does not explain 
the complicated AA pathogenesis, TLR receptors are one candidate category of molecules for 
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Fig 1. Expression of mRNA in peripheral blood mononuclear cells (PBMC) and follicular 
bulbs of AA affected scalp skin. QPCR revealed apparent marked increased expression of TLR9 
in PBMC, and IFNG and TLR7 in follicular bulbs (both perilesional and lesional margin 
combined). Y-axis indicates fold change in mRNA levels of target genes in AA related samples as 
compared to normal PBMC and hair follicles from controls. Bars represent the mean ± standard 






Fig 2. Expression of TLR7 and TLR9 in alopecia areata affected scalp skin. 
Immunohistochemistry for TLR7 (a) indicated TLR7 was present in the outer root sheath and hair 
matrix and possibly slightly expressed in the inflammatory infiltrate (arrow). TLR9 (b, c) 
expression was present in the inflammatory infiltrate cells (arrows) and possibly in the outer root 
sheath at a low level (c). Bar = 100μm (a, b); 50μm (c). 
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Supplemental Figure 1. Expression of mRNA in peripheral blood mononuclear cells 
(PBMCs) of patients categorized by extent of AA (SALT score). QPCR revealed apparent 
marked increased expression of TLR9 in the SALT score less than 30% group (P=0.024). Y-axis 
indicates fold change in mRNA levels of target genes in AA related samples as compared to 





Supplemental Figure 2. Expression of mRNA in peripheral blood mononuclear cells 
(PBMCs) of patients categorized by time duration of AA. QPCR revealed apparent increased 
expression, though not statistically significant (P=0.059), of TLR9 in the more than 6 months hair 
loss duration group. Y-axis indicates fold change in mRNA levels of target genes in AA related 





Supplemental Figure 3. Expression of mRNA in peripheral blood mononuclear cells 
(PBMCs) of patients categorized according to AA activity. QPCR revealed apparent marked 
increased expression of TLR9 in hair pull negative group (stable AA group; P=0.0009). IFNG 
exhibited significant decreased expression in the positive hair pull group (active AA group; 
P=0.014). Y-axis indicates fold change in mRNA levels of target genes in AA related samples as 
compared to normal PBMCs from controls. Bars represent the mean ± standard error. * indicates 





Supplemental Figure 4. Expression of mRNA in lesional margin and perilesional scalp hair 
follicles. QPCR revealed apparent marked increased expression of IFNG in perilesional AA hair 
follicles (P=0.038). Y-axis indicates fold change in mRNA levels of target genes in AA related 
samples as compared to normal hair follicles from controls. Bars represent the mean ± standard 
error. * indicates P-value ≤ 0.05. 
 
 
Supplemental Table 1. Sequences of primers used in qPCR (from 5’ to 3’) 
 
 
target gene forward primer sequence reverse primer sequence 
IFNG GGCATTTTGAAGAATTGGAAAG  GCTTTTCGAAGTCATCTCGTTT 
IFNGR1 GATGGAAAAATTGGACCACCTA ACTGGATCTCACTTCCGTTCAT 
IFNGR2 TGTTTACAAGTCCAGGCACAAC ATTTCAGGACCAGGAAGAAACA 
IFNA1 CAAAAGATTCATCTGCTGCTTG CAAGTCATTCAGCTGCTGGTAG 
IFNA2 CAAAAGATTCATCTGCTGCTTG CAAGTCATTCAGCTGCTGGTAG 
IFN-β1 TCCACTACAGCTCTTTCCATGA AGTATTCAAGCCTCCCATTCAA 
MX1 CACGAGTTCCACAAATGGAGTA TTCACGATTGTCTCAAATGTCC 
IFIT1 ACTTAAGGATGCAGCAAGAAGG CCATTTGTAAGTTCTCGAGGCTA 
IFI44 TTGGTGGGCACTAATACAACTG CCCCAGTGAGTCACACAGAATA 
IRF1 TGAGGATGAGGAAGGGAAATTA CTGGCTCCTCCTTACAGCTAAA 
GBP GATTGAAGTGGAACGTGTGAAA TCGTTCTCCATCTTCTCAGTCA 
TLR7 TTGAGAAGCCCTTTCAGAAGTC CACCTGACTATAGGCCACATGA 
TLR9 AGTTCTCTCTCCTGGCTGAATG GAAGGCCTTGGTTTTAGTGATG 
DDX58 CTCTTGATGCGTCAGTGATAGC CGAGGTCTTTGCAGATTCTCTT 
MDA5 GATAAGTGCATGGAGGAGGAAC TGGACAAGTTCATTGTTTCCTG 
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Supplemental Table 2. Significance of fold change in mRNA expression observed between 
AA patients and control samples 
 
Gene Follicular bulbs 




(all patients combined) 
Fold Change P-value Fold Change P-value 
IFNG 3.85 0.04 0.40 0.06 
IFNGR1 1.11 0.80 0.70 0.31 
IFNGR2 0.26 0.02 0.80 0.40 
IFNA1 0.41 0.02 0.76 0.69 
IFNA2 0.39 0.07 1.51 0.60 
IFNB1 1.08 0.88 0.59 0.37 
MX1 0.72 0.64 1.33 0.50 
IFIT1 0.14 0.00 1.31 0.54 
IFI44 0.48 0.22 0.92 0.87 
IRF1 0.93 0.85 0.84 0.55 
GBP 0.13 0.00 1.78 0.30 
TLR7 2.70 0.05 1.23 0.59 
TLR9 1.21 0.73 2.18 0.05 
DDX58 0.90 0.76 1.04 0.89 
MDA5 0.57 0.19 1.67 0.30 
 
 
 
